intestin
parasit
entamoeba
histolytica
e
histolytica
caus
agent
amoebiasi
diseas
fourth
caus
death
produc
protozoan
accord
world
health
organ
e
histolytica
infect
approxim
million
peopl
worldwid
howev
intra
hospit
variabl
incub
period
diseas
present
e
histolytica
infect
lead
million
report
case
invas
diseas
mortal
person
case
trophozoit
destroy
intestin
mucosa
spread
organ
bloodstream
produc
extraintestin
infect
common
amoeb
liver
treatment
intestin
extraintestin
amoebiasi
deriv
metronidazol
remain
first
therapeut
howev
class
drug
produc
undesir
side
effect
nausea
vomit
diarrhea
hypersensit
may
even
induc
sinc
introduct
metronidazol
treatment
amoebiasi
treatment
develop
nevertheless
diseas
still
respons
high
morbid
mortal
rate
worldwid
mainli
due
increas
resist
antiamoeb
hand
recent
year
interest
design
synthet
new
antiparasit
molecul
renew
facilit
applic
silico
dock
use
techniqu
sever
research
group
investig
newli
synthet
molecul
potenti
antiprotozo
compound
report
activ
molecul
e
histolytica
exampl
bioactiv
compound
tabl
use
present
work
valid
model
report
although
aforement
compound
possess
vitro
activ
e
histolytica
tissueact
drug
requir
treat
invas
amoebiasi
usual
evalu
either
vitro
andor
vivo
model
although
vivo
model
contribut
significantli
studi
amoebiasi
anim
model
mimic
whole
cycl
human
vitro
studi
axen
cultur
e
histolytica
howev
report
longterm
axen
cultiv
profound
effect
e
histolytica
virul
sever
virul
marker
cultur
condit
induc
strong
select
pressur
e
histolytica
sinc
amoeb
virul
vari
zero
highest
grade
vice
also
vitro
cultur
lack
complex
interact
stroma
compon
differ
cell
type
contribut
amoeba
pathogenesi
anim
regard
latter
ex
vivo
cultur
precisioncut
intestin
hepat
slice
repres
altern
model
contain
cell
type
belong
tissu
obtain
therefor
consid
miniorgan
slice
mani
advantag
vitro
vivo
system
ie
retain
metabol
transport
capac
among
previou
paper
group
report
hamster
liver
slice
infect
e
histolytica
repres
ex
vivo
model
studi
hepat
amoebiasi
base
morpholog
molecular
character
diseas
ex
studi
observ
morpholog
characterist
amoeba
conserv
evalu
experiment
time
eritophagocyt
activ
immun
respons
reaction
virul
factor
induct
furthermor
bansal
et
report
human
colon
explant
analyz
amoeb
virul
factor
reproduc
intestin
invas
e
histolytica
well
tissu
nonrespons
e
dispar
nonpathogen
speci
similarli
girardmisguich
et
util
porcin
colon
explant
deriv
miniatur
histocompat
sladd
piglet
cocultur
virul
imss
avirul
rahman
strain
e
histolytica
abl
observ
tissu
invas
trophozoit
typic
innat
immun
respons
similarli
report
human
colon
explant
likewis
ximenez
et
evalu
gene
relat
pathogen
e
histolytica
surviv
gene
link
immun
respons
precis
cut
liver
slice
human
tissu
afor
mention
studi
present
work
differ
origin
tissu
employ
hamster
pig
human
explant
prepar
methodolog
manual
semiautomat
cultur
media
amoeba
strain
virulentavirul
trophozoit
inocula
evalu
gene
host
parasit
gene
spite
technic
differ
tissu
explant
success
use
reproduc
infect
e
advantag
appli
one
principl
r
philosophi
reduc
number
anim
experiment
acquir
experi
use
liver
slice
cultur
present
work
implement
ex
vivo
cultur
intestin
slice
infect
model
e
histolytica
moreov
infect
precisioncut
hamster
liver
intestin
slice
use
analyz
antiamoeb
activ
time
possibl
toxic
amoebicid
molecul
infect
tissu
comparison
metronidazol
refer
compound
experiment
approach
allow
us
investig
effect
test
compound
e
histolytica
tissu
demonstr
feasibl
model
research
new
antiprotozo
drug
three
compound
effect
e
histolytica
valu
compound
cytotox
vitro
vero
cell
cultur
wherea
cytotox
result
select
index
si
two
compound
antiamoeb
activ
si
higher
refer
drug
metronidazol
si
result
summar
tabl
prepar
cultur
complet
tissu
slice
hamster
intestin
liver
success
establish
use
krumdieck
tissu
slicer
fig
slice
prepar
way
maintain
histolog
morpholog
characterist
normal
intestin
preserv
intestin
microvilli
fig
remain
viabl
incub
period
fig
experiment
infect
intestin
slice
also
achiev
success
figur
show
ulcer
mucosa
colon
due
infect
trophozoit
e
histolytica
amoeba
frequent
observ
close
contact
epitheli
cell
subsequ
penetr
mucosa
massiv
way
induc
mark
acut
inflammatori
respons
character
presenc
polymorphonuclear
cell
eosinophil
morpholog
event
relat
experiment
infect
observ
indistinctli
h
fig
b
h
fig
h
fig
f
import
mention
experiment
condit
amoeba
remain
viabl
healthi
infect
assay
judg
invas
abil
pseudopodia
format
chang
shape
insid
stromal
tissu
well
elev
erythrophag
activ
induct
characterist
tissu
lesion
observ
intestin
amoebiasi
expect
synthet
compound
show
ex
vivo
amoebicid
effect
intestin
fig
liver
fig
slice
infect
virul
trophozoit
e
histolytica
amoebicid
effect
compar
metronidazol
tissu
compound
induc
mark
decreas
number
trophozoit
fragmentationdisintegr
amoeba
regard
antiamoeb
effect
intestin
slice
repres
imag
control
infect
slice
cultur
h
presenc
absenc
compound
shown
fig
slice
cultur
cultur
medium
neg
control
histolog
structur
well
preserv
fig
meanwhil
infect
slice
numer
viabl
amoeba
intralumin
level
sever
acut
inflamm
ulcer
intestin
mucosa
intracrypt
abscess
frequent
observ
fig
expect
pharmacolog
control
metronidazol
induc
death
amoeba
therefor
decreas
number
fig
treatment
dirti
background
due
cell
debri
deriv
inflammatori
cell
usual
present
intestin
slice
infect
incub
synthet
compound
fig
decreas
number
amoeba
per
field
also
observ
similar
way
metronidazol
infect
slice
incub
presenc
synthet
compound
amoeba
disintegr
process
observ
less
extens
metronidazol
compar
compound
show
greater
amoebicid
effect
infect
tissu
liver
slice
infect
e
histolytica
trophozoit
treat
synthet
compound
fig
respect
mark
decreas
number
amoeba
per
microscop
field
fragment
amoeba
well
acut
inflammatori
respons
cell
frequent
seen
antiamoeb
effect
similar
metronidazol
fig
noninfect
slice
incub
presenc
synthet
compound
induc
regenerativeadapt
chang
microsteatosi
accompani
increas
ast
alt
level
respect
provok
focal
hepatocellular
necrosi
acut
inflamm
see
top
left
insert
fig
reflect
increas
level
alt
ast
nevertheless
compar
metronidazol
three
compound
significantli
less
hepatotox
fig
e
histolytica
enter
protozoan
caus
human
amoebiasi
consid
fourth
caus
parasit
metronidazol
nitroimidazol
deriv
often
select
drug
treat
amoebiasi
howev
drug
mutagen
carcinogen
mani
undesir
side
effect
amongst
other
likewis
appear
strain
e
histolytica
resist
convent
drug
given
aforement
search
new
antiamoeb
agent
continu
global
trend
differ
approach
taken
synthesi
new
systemat
studi
natur
antiamoeb
activ
tradit
test
vitro
use
axen
strain
e
addit
take
account
necessari
breakdown
intercellular
structur
infect
cell
line
mdck
use
interact
studi
silico
analysi
also
although
use
vitro
silico
assay
allow
screen
larg
number
molecul
record
time
scope
limit
result
obtain
question
sinc
model
reflect
vivo
situat
partial
allow
studi
drugparasitehost
great
import
studi
adher
parasit
e
histolytica
anim
model
also
use
studi
amoebiasi
howev
disadvantag
possibl
induc
intestin
hepat
lesion
anim
sinc
e
histolytica
infect
human
nonhuman
primat
result
obtain
vivo
studi
laboratori
anim
alway
translat
directli
human
practic
applic
use
vivo
test
investig
new
compound
molecul
antiamoeb
activ
limit
larg
number
anim
would
need
larg
amount
compound
requir
mention
implement
use
precisioncut
intestin
hepat
tissu
slice
altern
model
studi
antiamoeb
activ
compound
potenti
effect
e
histolytica
use
organ
anim
precisioncut
intestin
hepat
tissu
slice
consid
ex
vivo
model
intermedi
characterist
vitro
vivo
also
consid
miniorgan
metabol
capac
transport
metabol
chemic
present
work
describ
detail
implement
ex
vivo
infect
model
hamster
intestin
slice
e
histolytica
trophozoit
sinc
previous
report
use
hamster
liver
slice
infect
model
parasit
result
use
liver
slice
infect
amoeba
current
studi
ident
obtain
previou
also
valid
intestin
hepat
slice
experiment
infect
model
use
compound
known
antiamoeb
activ
current
studi
intestin
slice
cultur
h
presenc
amoeba
h
incub
total
investig
report
mainten
intestin
slice
viabil
similar
cultur
period
exampl
de
kanter
et
van
de
kerkhof
et
report
mainten
viabil
metabol
activ
h
cultur
two
hour
incub
use
analyz
interact
xenobiot
agent
transport
protein
author
shown
small
larg
intestin
slice
remain
viabl
h
respect
intracellular
atp
content
evalu
h
phase
ii
enzym
implic
metabol
transform
show
signific
chang
depend
origin
incub
time
tissu
slice
remain
viabl
depend
tissu
h
suitabl
liver
slice
intestin
slice
gener
term
abl
observ
typic
lesion
amoeb
diseas
ex
vivo
infect
pcl
pci
incub
longer
time
virul
strain
e
histolytica
caus
massiv
destruct
tissu
due
amoeba
infect
ensur
amoebicid
select
toxic
toward
amoeba
analyz
cytotox
effect
vitro
vero
cell
wellcharacter
kidney
deriv
cell
line
tumorigen
particular
passag
therefor
frequent
use
normal
cell
line
determin
toxic
preliminari
screen
sever
compound
biolog
sinc
vero
cell
use
select
compound
test
character
complex
system
found
concentr
use
test
harm
vitro
one
compound
show
vitro
cytotox
concentr
howev
decreas
cytotox
effect
concentr
compound
may
reduc
sinc
valu
vs
e
histolytica
one
main
challeng
ex
vivo
intestin
tissu
cultur
mainten
howev
present
studi
intestin
liver
slice
cultur
h
respect
infect
assay
maintain
metabol
viabil
evalu
alamar
blue
assay
data
shown
preserv
morpholog
structur
without
alter
result
similar
report
van
de
kerkhof
et
bansal
et
maintain
ex
vivo
tissu
cultur
h
h
respect
first
patholog
sign
observ
experiment
infect
intestin
tissu
slice
ulcer
mucosa
acut
inflamm
whilst
liver
slice
show
dilat
sinusoid
space
micro
abscess
numer
viabl
amoeba
seen
infect
tissu
even
though
tissu
slice
lack
bloodstream
observ
inflammatori
process
could
relat
specif
pattern
endogen
chemoattract
inflammatori
chemokin
produc
immun
cell
present
intestin
tissu
tissu
collect
sinc
known
gastrointestin
mucosa
largest
reservoir
macrophag
way
bansal
et
report
presenc
monocyt
tlymphocyt
within
lamina
propria
colon
explant
well
recruit
migrat
neutrophil
resid
immun
cell
site
infect
contribut
immun
respons
intestin
explant
suggest
intestin
tissu
slice
remain
immunolog
activ
fact
observ
histopatholog
chang
h
interact
e
histolytica
intestin
hepat
tissu
slice
suggest
infect
invas
process
start
time
addit
intracrypt
abscess
observ
h
incub
chang
similar
report
houpt
et
mice
infect
e
histolytica
also
observ
viabl
amoeba
area
epitheli
ulcer
sever
inflamm
reflect
presenc
plasma
cell
neutrophil
mast
cell
likewis
e
histolytica
trophozoit
degrad
intestin
epithelium
penetr
mucosa
human
intestin
explant
h
addit
bansal
et
report
trophozoit
reach
epitheli
surfac
remov
mucosa
detach
enterocyt
migrat
along
crypt
result
similar
obtain
present
work
inde
microscop
chang
describ
vivo
ex
vivo
model
sinc
prathap
gilman
espinosacantellano
human
amoeb
ulcer
result
lead
us
believ
experiment
model
intestin
hepat
tissu
slice
valuabl
tool
predict
effect
antiamoeb
compound
earli
stage
e
histolytica
infect
although
tissu
slice
well
accept
xenobiot
toxic
metabol
well
model
ex
vivo
infect
present
work
repres
first
report
situ
effect
compound
antiamoeb
properti
progress
infect
e
histolytica
organotyp
cultur
hepat
intestin
tissu
deriv
anim
therefor
signific
reduct
biolog
variabl
experiment
repetit
due
biolog
respons
anim
even
within
anim
current
well
known
liver
slice
repres
mini
liver
model
differ
cell
type
origin
microenviron
metabol
activ
wherea
cell
line
therefor
repres
suitabl
ex
vivo
model
measur
liver
damag
induc
differ
sinc
hepatotox
advers
reaction
may
induc
novel
compound
studi
model
capabl
predict
hepat
toxic
necessari
given
alt
ast
enzym
consid
sensit
biochem
indic
cellular
injuri
metabol
determin
enzym
level
hepat
slice
treat
synthet
compound
metronidazol
increas
level
alt
ast
enzym
indic
toxicolog
effect
test
therefor
increas
tissu
treat
confirm
cytotox
found
vero
cell
lower
select
si
compar
tissu
treat
toxic
vero
cell
exhibit
higher
select
si
also
induc
patholog
chang
histolog
level
induc
less
inflamm
necrosi
rais
one
two
hepat
enzym
nevertheless
compar
metronidazol
three
compound
significantli
less
toxic
tissu
cultur
use
concentr
although
compound
exert
cytotox
effect
vero
cell
well
known
vitro
test
use
cell
monolay
limit
model
differ
start
sinc
gener
dedifferenti
lack
amongst
other
transport
system
metabol
well
abil
maintain
histotyp
phenotyp
characterist
latter
may
explain
discrep
observ
vitro
studi
model
present
work
activ
compound
show
modest
cytotox
effect
intestin
liver
slice
much
lower
concentr
cytotox
seen
cell
line
similarli
van
de
kerkhof
et
show
high
metabol
rate
intestin
tissu
slice
time
higher
estim
hepatocyt
liver
tissu
slice
said
cultur
great
potenti
fill
gap
cellbas
research
anim
model
studi
hostpathogen
interact
well
contribut
develop
new
use
organotyp
cultur
understand
pathogenesi
differ
diseas
well
potenti
preclin
model
led
subsequ
applic
similar
model
alreadi
use
ex
vivo
model
respond
increasingli
clear
need
use
physiolog
relev
system
perform
better
vitroin
vivo
extrapol
iviv
mani
differ
diseas
like
amoebiasi
conclus
studi
demonstr
precisioncut
hamster
intestin
liver
slice
infect
e
histolytica
trophozoit
repres
model
allow
simultan
evalu
antiamoeb
potenti
new
compound
possibl
toxic
use
model
show
novel
synthet
compound
report
amoebicid
equal
effect
e
histolytica
golden
standard
metronidazol
current
use
treatment
diseas
without
compromis
tissu
viabil
great
extent
studi
protocol
approv
approv
nation
committe
scientif
research
instituto
mexicano
del
seguro
socia
imss
two
month
old
male
syrian
golden
hamster
mesocricetu
auratu
obtain
anim
facil
northeast
biomed
research
center
imss
monterrey
use
anim
kept
polycarbon
cage
free
access
food
water
anim
handl
accord
intern
principl
ethic
manag
care
accord
offici
mexican
norm
nom
technic
specif
product
care
use
laboratori
anim
guidelin
institut
biosecur
committe
imss
manual
procedur
recommend
anim
research
method
perform
accord
approv
guidelin
virul
trophozoit
e
histolytica
strain
cultur
maintain
axen
trypticaseyeast
extractironserum
medium
supplement
bovin
serum
penicillinstreptomycin
vitamin
subcultur
bioassay
perform
amoeba
logarithm
phase
growth
synthet
compound
synthet
identifi
accord
method
report
et
preliminari
step
analysi
antiamoeb
activ
synthet
compound
intestin
hepat
tissu
slice
possibl
cytotox
vero
cell
cultur
evalu
cell
line
use
worldwid
assess
vitro
cytotox
effect
andor
select
index
differ
addit
vero
cell
endors
iso
expert
suitabl
test
cytotox
certain
compound
materi
medic
cell
line
cultur
eagl
minimum
essenti
medium
supplement
fetal
bovin
serum
vv
mixtur
iuml
streptomycin
cytotox
analysi
confluent
logarithm
growth
phase
cultur
use
seed
well
plate
micropl
incub
overnight
compound
ad
concentr
rang
incub
addit
h
humid
atmospher
viabil
cell
incub
presenc
determin
assay
directli
proport
number
viabl
assay
carri
duplic
entir
process
perform
steril
condit
shortest
time
surgic
manipul
order
minim
autolysi
intestin
tissu
due
ischemia
briefli
hamster
receiv
intraperiton
inject
sodium
pentobarbit
mg
g
weight
deep
anesthesia
colon
portion
larg
intestin
care
remov
divid
fragment
three
centimet
long
fragment
place
krebshenseleit
buffer
kb
buffer
wash
buffer
remov
intestin
content
superfici
adipos
tissu
care
remov
afterward
intestin
fragment
tie
use
surgic
thread
one
end
opposit
side
fill
low
melt
point
agaros
place
kb
buffer
agaros
solidif
fragment
intestin
fill
agaros
place
tissu
embed
unit
krumdieck
tissu
slicer
order
prepar
regular
agaros
cylind
cylind
place
sampl
holder
krumdieck
tissu
slicer
intestin
tissu
slice
thick
prepar
alway
constant
recircul
kb
buffer
gass
carbogen
slice
collect
kb
buffer
remov
extern
ring
agaros
aid
spatula
figur
show
gener
aspect
process
prepar
intestin
hepat
slice
intestin
slice
obtain
best
macroscop
appear
select
subsequ
two
slice
place
per
well
micropl
well
contain
ml
medium
supplement
fetal
bovin
serum
mm
glucos
mgl
gentamicin
subsequ
preincub
h
cell
cultur
incub
stabil
tissu
intestin
slice
infect
virul
trophozoit
e
histolytica
suspend
ml
mix
medium
complet
medium
control
noninfect
slice
use
micropl
incub
rest
h
allow
adher
amoeba
tissu
time
slice
transfer
steril
condit
anoth
micropl
contain
ml
mix
media
two
wash
perform
kb
buffer
elimin
amoeba
attach
intestin
tissu
infect
slice
incub
ml
medium
agit
rpm
sampl
taken
h
subsequ
analysi
obtain
ex
vivo
cultur
hamster
liver
slice
well
subsequ
experiment
infect
carri
accord
protocol
previous
describ
research
ex
vivo
infect
intestin
liver
slice
e
histolytica
trophozoit
slice
tissu
preincub
separ
micropl
ml
complet
cultur
medium
h
ad
triplic
well
concentr
correspond
compound
previous
report
vitro
et
metronidazol
use
refer
amoebicid
drug
wherea
dmso
cultur
medium
use
solvent
control
neg
control
respect
infect
control
slice
well
treat
synthet
compound
incub
agit
rpm
h
intestin
tissu
h
liver
tissu
end
incub
slice
fix
neutral
formalin
histopatholog
analysi
three
independ
experi
perform
cellspecif
biomark
analyz
includ
ast
aspart
aminotransferas
alt
alanin
aminotransferas
liver
parenchyma
alt
ast
enzym
consid
sensit
biochem
indic
use
evalu
cellular
injuri
metabol
disturb
enzym
inactiv
induct
exogen
chemic
presenc
liver
effluent
reflect
hepatocyt
lysi
consequ
chronic
inflamm
sourc
liver
evalu
possibl
tissu
toxic
synthet
compound
liver
slice
incub
h
presenc
concentr
use
infect
assay
incub
hepat
enzym
alt
ast
measur
describ
behrs
et
briefli
liver
slice
remov
micropl
well
gentli
rins
pb
afterward
slice
transfer
ml
potterelvehjem
tissu
grinder
contain
ml
pb
triton
ice
homogen
slice
result
lysat
centrifug
g
min
remov
particul
matter
result
supernat
analyz
hitachi
clinic
analyz
three
independ
experi
perform
incub
time
slice
wash
pb
fix
buffer
formalin
h
room
temperatur
dehydr
clarif
process
paraffin
block
prepar
treatment
section
thick
prepar
use
convent
microtom
section
stain
hematoxylin
eosin
h
e
observ
light
field
microscop
histopatholog
criteria
integr
nucleu
cytoplasm
cell
membran
well
degre
cellular
damag
interact
trophozoit
intestin
hepat
tissu
use
order
evalu
morpholog
characterist
tissu
effect
induc
treatment
synthet
compound
metronidazol
morpholog
paramet
determin
infect
control
slice
data
control
treatment
group
analyz
use
ttest
analysi
valu
consid
significantli
differ
p
spss
softwar
version
use
